Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension.
Mattias ArvidssonAbdulla AhmedHabib BouzinaGöran RådegranPublished in: ESC heart failure (2021)
Plasma prolargin levels differentiate PAH patients from controls and the other investigated dyspnoea groups including HF. Its potential in PAH differentiation may be enhanced by inclusion in a multi-marker panel. Larger studies are needed to evaluate its discriminative ability of PAH in relation to other dyspnoea aetiologies and its potential role in PAH risk stratification and pathobiology.
Keyphrases
- pulmonary arterial hypertension
- polycyclic aromatic hydrocarbons
- end stage renal disease
- pulmonary artery
- pulmonary hypertension
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- heart failure
- coronary artery
- patient reported outcomes
- mass spectrometry
- high resolution